Banks Will Shine In 2025, Analyst Says, But Can They Dodge Loan Losses?
HSBC analyst revises ratings on banks, expects improved NII, EPS growth, leverage, buybacks. Upgrades US Bancorp, PNC, downgrades Bank of America.
Amgen’s Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says
Raymond James resumes coverage of Amgen highlighting its diversified portfolio and strong presence across therapeutic areas for sustainable long-term growth. Innovative pipeline in oncology, rare diseases, and obesity offers promise, though uncertainties remain."
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What’s Driving Markets Thursday?
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.
Easter’s Bitter Surprise: Cocoa Is Up 240% In A Year – What Can A Ton Of The Chocolate Commodity Get You Today?
Cocoa prices surged to a staggering $10,000 in the last week of March 2024, marking an unprecedented 240% increase from the previous year that’s bound to affect chocolate lovers this Easter.
Johnson & Johnson Has An Opportunity In Talc-Cancer Lawsuit, Can Challenge Scientific Evidence In Federal Ruling
Johnson & Johnson faces legal scrutiny over talc-cancer link. Recent rulings could impact 53,000+ lawsuits. Learn more about the $700 million settlement and evolving evidence in this ongoing litigation. J&J refutes claims, but legal battles continue.
How Much Does It Cost To Make Novo Nordisk’s Ozempic? Shockingly Low Against $1,000 Price Tag, Study Shows
Study reveals stark contrast: Novo Nordisk's Ozempic diabetes drug costs nearly $1,000 monthly in the U.S., yet could be produced for less than $5. This underscores the affordability challenge faced by patients amid soaring demand and insurers dropping coverage.
UnitedHealth’s Cyberattack – Company Provides Aid Of Over $3B To Affected Providers
UnitedHealth reveals $3.3 billion advance payments to healthcare providers after a cyberattack on Change Healthcare's claims system. Financial aid targets safety net hospitals and clinics. Incident prompts federal investigation and cybersecurity reevaluation in the healthcare sector.
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session – Here’s Why
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered royalties on global sales.
Insurance Coverage For Weight Loss Drugs – Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk’s Successful Wegovy For Certain Patients
Major U.S. health insurers CVS Health, Elevance Health, and Kaiser Permanente now reimburse for Novo Nordisk's Wegovy for specific Medicare individuals with heart-related conditions. This shift aims to alleviate financial burden and may prompt broader coverage, potentially impacting drug spending.
Home Depot Scores Big With $18.25B SRS Acquisition, Boosts Addressable Market To $1T
Home Depot will acquire SRS Distribution Inc. for $18.25B. The deal is expected to close by end of fiscal 2024 and be dilutive to GAAP EPS but accretive from a cash EPS perspective.